Hospital
North Sunflower Medical Center
North Sunflower Medical Center was paid $15.90M by Medicaid between Jan 2018 and Dec 2024, across 186 billing codes. Its largest line is 90853, Group psychotherapy (other than of a multiple-family group) — 15% of everything it billed.
33Billing provider infoNORTH SUNFLOWER MEDICAL CENTER
RULEVILLE, MS 38771
RULEVILLE, MS 38771
33aNPI1508913609assigned 01/04/2007
33bProvider typeCritical Access Hospital
28Total paid$15.90M
24GClaims425,408
24DCodes billed186
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Mississippi
Rank by total paid#1 of 32
Median peer was paid$3.94M
This provider vs. median4.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 70,302 | $3.38M | |
| 2019 | 59,491 | $2.07M | |
| 2020 | 53,721 | $1.60M | |
| 2021 | 66,698 | $2.41M | |
| 2022 | 71,957 | $2.44M | |
| 2023 | 58,569 | $2.14M | |
| 2024incomplete | 44,670 | $1.86M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 90853 | Group psychotherapy (other than of a multiple-family group) | 15% | 15,753 | 1,623 | $2.34M |
| D7210 | Extraction, erupted tooth requiring removal of bone and/or sectioning of tooth | 10% | 7,786 | 2,329 | $1.59M |
| D7240 | Removal of impacted tooth - completely bony | 7.7% | 4,641 | 1,974 | $1.22M |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 5.8% | 30,680 | 23,704 | $917K |
| D7140 | Extraction, erupted tooth or exposed root | 4.7% | 3,392 | 1,250 | $754K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.6% | 22,271 | 2,617 | $737K |
| 41874 | 3.9% | 540 | 295 | $616K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 3.1% | 23,936 | 19,128 | $494K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.0% | 7,293 | 5,157 | $473K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 2.8% | 7,797 | 5,725 | $453K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.5% | 6,128 | 3,192 | $397K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.2% | 10,507 | 1,957 | $344K |
174 more codes
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.6% | 9,249 | $257K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 4,273 | $241K |
| 71046 | Radiologic examination, chest; 2 views | 1.5% | 8,578 | $234K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 4,067 | $229K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.3% | 2,239 | $212K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.3% | 5,991 | $201K |
| 80053 | Comprehensive metabolic panel | 1.3% | 23,859 | $199K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.2% | 10,444 | $192K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 33,408 | $186K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 855 | $185K |
| D7230 | 1.1% | 827 | $180K | |
| 99284 | Emergency room visit (serious) | 1.1% | 4,028 | $179K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 8,152 | $171K |
| 99285 | Emergency room visit (most serious) | 1.1% | 1,752 | $170K |
| D7241 | 1.0% | 426 | $165K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,387 | $158K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 292 | $114K |
| 73564 | <1% | 2,041 | $97K | |
| D7220 | <1% | 404 | $93K | |
| D7250 | <1% | 691 | $86K | |
| G0378 | Hospital observation service, per hour | <1% | 507 | $82K |
| 83880 | <1% | 3,898 | $78K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,405 | $74K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 617 | $65K |
| D0330 | Panoramic radiographic image | <1% | 2,396 | $64K |
| 84703 | <1% | 7,063 | $63K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,981 | $59K |
| 94726 | <1% | 727 | $55K | |
| 80061 | Lipid panel | <1% | 5,088 | $51K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,623 | $49K |
| 74018 | <1% | 1,532 | $48K | |
| 84484 | <1% | 6,890 | $47K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,332 | $44K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,983 | $43K |
| 94060 | <1% | 484 | $41K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 19,189 | $41K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,048 | $41K |
| 82553 | <1% | 6,234 | $41K | |
| 97116 | <1% | 1,692 | $39K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,499 | $38K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,488 | $37K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,337 | $37K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 157 | $37K |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 134 | $34K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,014 | $34K |
| 87807 | <1% | 3,149 | $31K | |
| 83735 | <1% | 7,245 | $30K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,352 | $29K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 64 | $27K |
| 74019 | <1% | 542 | $26K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 763 | $24K |
| 73630 | <1% | 727 | $24K | |
| 80074 | <1% | 819 | $24K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,263 | $24K |
| 72110 | <1% | 596 | $23K | |
| J2357 | Injection, omalizumab, 5 mg | <1% | 19 | $23K |
| 73130 | <1% | 615 | $23K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,812 | $19K |
| 73030 | <1% | 564 | $16K | |
| 81001 | <1% | 4,823 | $15K | |
| 87088 | <1% | 2,810 | $15K | |
| 85730 | <1% | 4,326 | $15K | |
| 82607 | <1% | 1,468 | $14K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 32 | $14K |
| 86703 | <1% | 1,313 | $13K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,073 | $13K |
| 83690 | <1% | 2,877 | $13K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 413 | $13K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 146 | $13K |
| 85610 | <1% | 4,973 | $12K | |
| 87040 | <1% | 1,143 | $12K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 208 | $10K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 385 | $10K |
| 87077 | <1% | 1,734 | $9K | |
| 80305 | <1% | 1,207 | $9K | |
| 73610 | <1% | 242 | $9K | |
| 86696 | <1% | 708 | $9K | |
| 82150 | <1% | 1,984 | $9K | |
| 97161 | <1% | 236 | $9K | |
| 87184 | <1% | 1,721 | $9K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 525 | $8K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 52 | $8K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 282 | $7K |
| 94010 | <1% | 215 | $7K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,658 | $7K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 44 | $6K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 15 | $6K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 103 | $6K |
| 87428 | <1% | 102 | $5K | |
| 74178 | <1% | 34 | $5K | |
| 86677 | <1% | 615 | $5K | |
| 96367 | <1% | 344 | $5K | |
| 93925 | <1% | 85 | $5K | |
| 87590 | <1% | 302 | $5K | |
| 83540 | <1% | 1,104 | $4K | |
| 81003 | <1% | 2,885 | $4K | |
| 94150 | <1% | 451 | $4K | |
| 87490 | <1% | 307 | $4K | |
| 87486 | <1% | 156 | $4K | |
| 87581 | <1% | 156 | $4K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 40 | $4K |
| 51702 | <1% | 117 | $3K | |
| 82746 | <1% | 367 | $3K | |
| 85379 | <1% | 573 | $3K | |
| D7280 | <1% | 19 | $3K | |
| 93017 | <1% | 83 | $3K | |
| 95811 | <1% | 18 | $3K | |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 80 | $3K |
| 86592 | <1% | 966 | $3K | |
| 73502 | <1% | 117 | $3K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 149 | $3K |
| 83655 | <1% | 203 | $3K | |
| 82728 | <1% | 294 | $2K | |
| 94200 | <1% | 451 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 156 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 341 | $2K |
| 74021 | <1% | 56 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 33 | $2K |
| 73110 | <1% | 38 | $2K | |
| 93922 | <1% | 60 | $2K | |
| 94375 | <1% | 364 | $1K | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 1,453 | $1K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,799 | $942.30 |
| 81015 | <1% | 416 | $939.62 | |
| 87070 | <1% | 106 | $938.25 | |
| 73620 | <1% | 27 | $901.54 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,252 | $771.58 |
| D9310 | <1% | 14 | $761.48 | |
| 51701 | <1% | 29 | $744.96 | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 28 | $710.53 |
| 73560 | <1% | 20 | $648.50 | |
| 83550 | <1% | 127 | $646.13 | |
| 98967 | <1% | 82 | $630.00 | |
| D1120 | Dental cleaning, child | <1% | 78 | $596.87 |
| 80185 | <1% | 44 | $547.52 | |
| 82962 | <1% | 321 | $500.34 | |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | <1% | 33 | $470.21 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,272 | $424.31 |
| D1206 | Topical application of fluoride varnish | <1% | 75 | $394.86 |
| 71047 | <1% | 169 | $347.60 | |
| 82550 | <1% | 72 | $329.14 | |
| 82803 | <1% | 16 | $328.44 | |
| 80164 | <1% | 28 | $304.75 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 94 | $262.04 |
| 85651 | <1% | 68 | $226.74 | |
| 83026 | <1% | 78 | $222.83 | |
| 84439 | <1% | 42 | $219.24 | |
| 94729 | <1% | 195 | $218.97 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 12 | $191.18 |
| 86140 | <1% | 72 | $172.42 | |
| 87808 | <1% | 16 | $151.36 | |
| 85014 | <1% | 94 | $144.25 | |
| 82565 | <1% | 28 | $77.54 | |
| 87905 | <1% | 16 | $74.67 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 136 | $68.98 |
| 84520 | <1% | 28 | $62.84 | |
| 96376 | <1% | 217 | $50.00 | |
| 87220 | <1% | 16 | $47.54 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 41 | $39.83 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 56 | $20.00 |
| 82247 | <1% | 21 | $13.56 | |
| 84132 | <1% | 19 | $10.08 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 31 | $7.39 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 14 | $1.28 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 110 | $0.00 |
| 0240U | 0% | 554 | $0.00 | |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 293 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 16 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 33 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 48 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 74 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 141 | $0.00 |
| A9520 | Technetium tc-99m tilmanocept, diagnostic, up to 0.5 millicuries | 0% | 47 | $0.00 |
| S0077 | Injection, clindamycin phosphate, 300 mg | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCEJA, JOSE (CEO)
| Provider | Location | Paid |
|---|---|---|
| North Sunflower Medical Center | Ruleville, MS | $15.29M |
| North Sunflower Medical Center | Ruleville, MS | $1.50M |
| North Sunflower Medical Center Dentists | Ruleville, MS | $1.45M |
| North Sunflower Medical Center | Ruleville, MS | $379K |
| North Sunflower Medical Center | Ruleville, MS | $112K |
| North Sunflower Medical Center | Ruleville, MS | $57K |
| North Sunflower Medical Center | Ruleville, MS | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.